ArticlePloS one2025

Study protocol: Exploratory trial of Forza™, an osmotin-based nutraceutical as adjuvant for the treatment of progressive multiple sclerosis.

Viola Costa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.